PERINATAL STEM CELLS. RESEARCH AND THERAPY

• Section I. Amniotic Fluid-Derived Stem Cells
1. In utero therapy for congenital disorders using amniotic fluid stem cells
2. The Amniotic Fluid Stem Cell Secretome: at the Heart of Regeneration
3. Transplantation of Amniotic Fluid-Derived Neural Stem Cells
4. Stroke therapy: the potential of amniotic fluid-derived stem cells
5. Vascular formation by human perinatal stem cells
6. Amniotic Fluid Stem Cells for Kidney Regeneration
• Section II. Placental and Placental Membrane-Derived Stem Cells
7. Placental mesenchymal stem cells for cellular cardiomyoplasty
8. Heterogeneous functions of perinatal mesenchymal stromal cells require a preselection before their banking for clinical use
9. Defining the fetal stem cell niche in the human placenta
10. Banking placental tissue hematopoietic stem cells and mesenchymal stem cells for clinical use
11. Immuno-modulatory mechanisms of placental stem cells
12. Amnion Membrane Allograft for Regenerative Medicine
13. Placental Stem Cells
14. Therapeutic Effect of Extracellular Vesicles Derived from Adult/Perinatal Human Mesenchymal Stem Cells
• Section III. Umbilical Cord-Derived Cells
15. Ex-vivo Expansion of Cord Blood Stem Cells
16. Cord Blood Transplantation: Therapeutic Use of Perinatal Stem Cells
17. Autologous Human Cord Blood as a Treatment for Traumatic Brain Injury in Children
18. Phenotypic and Functional Characterization Perinatal Stem Cells Isolated from Umbilical Cord Tissue
19. Mesenchymal stromal cells from Wharton’s jelly (WJ-MSCs): coupling their hidden differentiative program with their frank immunomodulatory phenotype
20. Regeneration of ischemic cardiovascular damage using Jelly Wharton as an unlimited source of therapeutic stem cells
21. Phenotype with Focused Paracrine Fractions: Effecting Future Phenotype with Focused Paracrine Fractions
• Section IV. Clinical and Industry Perspective
22. Clinical Translation of Perinatal Stem Cell Therapy
23. Current Clinical Trials utilizing Perinatal Stem Cells – A Review
24. Review Of Processing Technology and Techniques for Perinatal Stem Cells Banking And Clinical Applications
25. Clinical Development And Commercialization Of Placenta-Derived Cell Therapy
26. How the patent landscape has changed
27. The Need for Better Assays to Predict the Effectiveness of Tissue Stem Cell Treatments

• Explores current clinical and pre-clinical application of stem cells derived from perinatal sources
• Offers detailed insight into sources of perinatal stem cells and their potential for disease treatment
• Discusses progress in the manufacturing, banking and clinical translation of perinatal stem cells
• Edited by a world-renowned team to present a complete story of the development and promise of perinatal stem cells

Authors
• Anthony Atala, Department of Urology, Wake Forest Institute for Regenerative Medicine, Wake Forest University, Winston-Salem, NC, USA;
• Kyle J. Cetrulo, Chief Executive Officer, AuxoCell Laboratories, Inc., Cambridge, MA, USA;
• Rouzbeh R. Taghizadeh, Co-Founder, Chief Scientific Officer, AuxoCell Laboratories, Inc., Cambridge, MA, USA ;
• Curtis L Cetrulo, Assistant Professor, Surgery, Harvard Medical School, Plastic and Reconstructive Surgery, Surgery, Massachusetts General Hospital, USA.
• Sean Murphy, Assistant Professor, Wake Forest Institute for Regenerative Medicine, USA